FINWIRES · TerminalLIVE
FINWIRES

沙特证券交易所(Tadawul)股价收高;沙特阿拉伯将主办海湾合作委员会峰会,讨论伊朗-美国战争问题。

By

-- 沙特阿拉伯交易所股票周二收高,Tadawul全股指数上涨0.10%,投资者正在评估伊朗-美国冲突的最新进展。 一位美国官员表示,唐纳德·特朗普总统对伊朗的提议“不满意”。伊朗的提议建议搁置核谈判,直到霍尔木兹海峡的封锁问题得到解决。 “《华尔街日报》隔夜报道称,特朗普及其官员对伊朗提出的(我们昨天提到的)在搁置核谈判的同时重新开放霍尔木兹海峡的提议持怀疑态度。《华尔街日报》的报道暗示,白宫可能会在未来几天向德黑兰提出反提案。白宫新闻秘书莱维特昨天早些时候表示,特朗普周一上午与国家安全官员讨论了伊朗的提议,并坚持在任何结束战争的协议上划定‘红线’。”德意志银行研究部在一份报告中指出。 此外,沙特阿拉伯将在吉达与海湾合作委员会领导人举行峰会。会谈将重点讨论如何应对伊朗在该地区发动的袭击。 在企业方面,沙特地面服务公司(SASE:4031)获得了一份为期五年的合同,将在利雅得哈立德国王国际机场提供旅客登机桥服务。这家客运和飞机地面服务公司的股价收盘上涨0.06%。 与此同时,据路透社援引对亚洲炼油商的调查报道,沙特阿拉伯预计将在6月份将其旗舰产品阿拉伯轻质原油的亚洲出口价格下调5至12美元/桶。报道称,此举是由于原油需求降温所致。

Related Articles

Sectors

Sector Update: Tech Stocks Fall Late Afternoon

Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.

$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research

Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.

$PCAR
Australia

Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data

Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%

$ERAS